This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Joshi TP, Friske SK, Hsiou DA. New Practical Aspects of Sweet Syndrome. Am J Clin Dermatol. 2022;23:301–318.Search in Google Scholar
Heath MS, Ortega-Loayza AG. Insights Into the Pathogenesis of Sweet’s Syndrome. Frontiers in Immunology. 2019:10.Search in Google Scholar
NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411. (5 April 2023)Search in Google Scholar
Sweet RB. An acute febrile neutrophtlic dermatosis. Br J Dermatol. 1964;76:349–356.Search in Google Scholar
Olguín-Ramírez LA, Jaime-Pérez JC, Mendoza-Rodríguez C, Gómez-Almaguer D. Sweet syndrome presenting late after nonHodgkin’s lymphoma and dermatomyositis. Medicina Universitaria. 2014;16:25–27.Search in Google Scholar
Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A. Sweet Syndrome: A Review and Update. Actas Dermosifiliogr. 2016;107:369–378.Search in Google Scholar
Cohen PR. Sweet’s syndrome-a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34.Search in Google Scholar
Hung YT, Huang YL, WU J. Drug-Induced Subcutaneous Seet Syndrome. Mayo Clin Proc. 2023;98:631–632.Search in Google Scholar
Ferea CR, Mihai SN, Balan G, Badescu MC, Tutunaru D, Tatu AL. Sweet Syndrome Associated with Myelodysplastic Syndrome – A Review of a Multidisciplinary Approach. Life (Basel). 2023;13:809.Search in Google Scholar
Martinelli S, Rigolin GM, Leo G. Complete remission of Sweet’s syndrome after azacytidine treatment for concomitant myelodysplastic syndrome. Int J Hematol. 2014;99:663–667.Search in Google Scholar
Kazmi SM, Pemmaraju N, Patel KP, Cohen PR. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2015;15:358–363.Search in Google Scholar
Majmundar VD, Baxi K. Acute Febrile Neutrophilic Dermatosis. https://www.ncbi.nlm.nih.gov/books/NBK559142/. (January 2023)Search in Google Scholar
Vashisht P, Goyal A, Hearth Holmes MP. Sweet Syndrome. https://www.ncbi.nlm.nih.gov/books/NBK431050/. (January 2023)Search in Google Scholar
Maller B, Bigness A, Moino D, Greene J. Sweet’s syndrome associated with hematological malignancies. Leuk Res. 2020;99:106461.Search in Google Scholar
Waghmare P, Patra S, Thirunavukkarasu B, Bairva S. Azacytidine-induced Sweet’s syndrome. BMJ Case Reports CP. 2022;15:252329.Search in Google Scholar
Okura T, Aboulafia DM, Picozzi V. Sweet’s Syndrome: A Frequently Unrecognized Complication Following Acute Myeloid Leukemia (Aml) Induction Chemotherapy: A Case Report. Blood. 2006;108: 4547.Search in Google Scholar
Kaminskas K, Farrel AT, Wang YC. FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza) for Injectable Suspension. The Oncologist. 2005;10:176-182.Search in Google Scholar
Trickett HB, Cumpston A, Craig M. Azacitidine-associated Sweet’s syndrome. Am J Health Syst Pharm. 2012;69:869–871.Search in Google Scholar
Troccola A, Fino P, De Santo L, Corrias F. Sweet’s Syndrome as a Possible Consequence of Azacitidine Subcutaneous Administration in IPSS Intermediate-2 Myelodysplastic Syndrome. J Blood Disord Transfus. 2015;6:4.Search in Google Scholar
Doodnauth A, Omar K, Anees R, Arancibia R. Azacitidine-Induced Sweet Syndrome: A Unique Presentation. Chest. 2021;160:840.Search in Google Scholar
